CohBar is a clinical stage biotechnology company utilizing the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In addition, Co. has multiple preclinical programs, such as a program in acute respiratory distress syndrome as well as earlier stage discovery programs. Co.'s pipelines include: CB5138-3, which is for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases; CB4211, which is for the treatment of nonalcoholic steatohepatitis and obesity; and CB5064 Analogs, family of peptides that are agonists of the apelin receptor.
|
Free CWBR Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |